News
Print
August 20, 2009
NORTH BRUNSWICK, N.J.--(August 20, 2009) --Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.
This technology enables a single vaccine to simultaneously attack two separate and distinct tumor targets with a higher level of potency. Further investigational work is focusing on the use of this dual delivery approach directed against a tumor cell surface marker to kill tumor cells directly plus an anti-angiogenic target that would impair a tumor’s ability to grow by simultaneously reducing its blood supply.
“Advaxis continues to invent new ways to use the very powerful live Listeria vaccine platform to treat disease,” commented Advaxis CEO Thomas A. Moore. “The remarkably broad and effective immune response to Listeria vaccines enables us to work with a wide variety of different antigens in order to maximize their efficacy; and now we can work with more than one antigen at a time.”
About the Company
Advaxis is a biotechnology company developing proprietary, attenuated, live Listeria monocytogenes (Lm) vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer. Based in North Brunswick, NJ, the Company’s drug platform is based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. For further information on the Company, please visit:www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
